Nov. 15, 2014
A presentation regarding the results of the HALT-PKD clinical trial was shared this morning at the American Society of Nephrology (ASN) Kidney Week meeting.
The HALT study is important to the PKD community because neither the optimal blood pressure target levels, nor the best medications for control of blood pressure in ADPKD, were known when the study was started in 2006 (the study was completed in June 2014). Currently, the complications of hypertension, including stroke and heart attack, affect many more individuals with ADPKD than ADPKD-specific complications such as liver cysts or brain aneurysms.
According to the New England Journal of Medicine: "These two studies provide important guidance for the care of patients with ADPKD. They show that blood pressure can be controlled with ACE inhibitors, drugs that have an acceptable safety profile. They suggest that rigorous blood-pressure control, early in the disease process, may slow cyst growth and reduce the left-ventricular-mass index, but this approach is complicated by increased dizziness."